盘点:Diabetes Care 19年1月刊重要原始研究汇总

2019-01-19 MedSci MedSci原创

【1】年轻1型糖尿病患者终末期肾病累积发病率降低DOI:10.2337/dc18-1276糖尿病肾病是1型糖尿病的严重并发症。最近的研究表明,终末期肾病(ESRD)的发病率已经下降或者ESRD的发病已经推迟。近日,研究人员分析了瑞典ESRD的发病率和时间变化趋势。在这项研究中,研究人员纳入了病程>14年且糖尿病发病年龄为0-34岁的1型糖尿病患者。研究人员使用了三个国家糖尿病登记中心:瑞

【1】年轻1型糖尿病患者终末期肾病累积发病率降低

DOI:10.2337/dc18-1276

糖尿病肾病是1型糖尿病的严重并发症。最近的研究表明,终末期肾病(ESRD)的发病率已经下降或者ESRD的发病已经推迟。近日,研究人员分析了瑞典ESRD的发病率和时间变化趋势。在这项研究中,研究人员纳入了病程>14年且糖尿病发病年龄为0-34岁的1型糖尿病患者。研究人员使用了三个国家糖尿病登记中心:瑞典儿童糖尿病登记中心、瑞典糖尿病发病率研究和国家糖尿病登记中心。瑞典肾脏登记处是瑞典全国肾脏替代治疗登记处,用于确定发生发展为ESRD的患者。研究人员发现瑞典ESRD的累积发病率在糖尿病患病时间持续长达38年之后仍然很低(5.6%)。与1977-1984和1985-1990的发病率相比,1991-2001年期间1型糖尿病患者发生ESRD的发生率较低,且与糖尿病病程无关。由此可见,在瑞典1型糖尿病患者人群中发生ESRD的风险仍然很低,而且似乎也随着时间的推移而有所降低。

【2】晚发T1DM和较大年龄可预测其它自身免疫性疾病的风险

DOI:10.2337/dc18-1157


1型糖尿病(T1DM)与其他自身免疫性疾病(AID)有关,这些AID可能对健康造成严重后果。T1DM患者中AID的流行病学尚未明确。近日,一项横断面队列研究中,研究人员试图描述各年龄段T1DM成人AID的发病年龄和患病率。研究人员纳入在2011年至2018年期间到华盛顿大学糖尿病中心就诊的1212名成年人,并收集了患者的年龄、性别、种族和发病数据。结果显示,AID发病率和患病率随年龄增长而增加。女性可强烈预测AID风险。最常见的T1DM相关AID是甲状腺疾病、胶原血管疾病和恶性贫血。T1DM发病年龄和T1DM持续时间可预测AID风险。30岁以后的晚发性T1DM患者发生其它AID的风险高于T1DM发病年龄较小的患者。由此可见,T1DM患者的AID患病率随着年龄的增长和女性而增加。T1DM的晚期发病是发生其它AID的独立且重要的危险因素。在老年人中被诊断患有T1DM的个体,特别是女性,应该监测其它自身免疫疾病。

【3】BMI高合并子痫前期,增加产后T2DM风险

DOI:10.2337/dc18-1532


瑞典隆德大学Simon Timpka及其同事指出,有HDP病史的女性维持健康体重会有额外获益,因为产后BMI可介导HDP病史与慢性高血压事件之间的关系。然而,有HDP病史的女性保持健康BMI是否比无HDP病史的女性在预防T2DM方面更重要尚不明确。研究者对护士健康研究Ⅱ中56 159例女性数据进行了分析,平均年龄46.3岁。其中,6563例(11%)女性有HDP病史。受试者于1991~2013年接受随访,完成生育史调查问卷,以确认子痫前期或妊娠高血压情况。研究期间,受试者每2年完成一次调查问卷以确认T2DM诊断。该研究结果表明,BMI高且有HDP病史的女性患T2DM的风险高于预期。这项研究进一步支持HDP病史是代谢易感性的一种标志,可能在产后几年与BMI协同作用进一步增加T2DM发生风险。

【4】1型糖尿病患者肾移植后长期死亡率情况

DOI:10.2337/dc18-1029


近日,一项研究中,研究人员旨在评估透析和肾移植后1型糖尿病和终末期肾病患者死亡率和死亡原因的时间趋势。在这项全国性的回顾性队列分析中,纳入了芬兰所有单独接受肾移植的1型糖尿病患者,与仍在进行透析的患者进行比较。研究人员分析了2383名患者。移植成功后患者存活期的中位数为15.9年,如果移植失败则存活11.2年,如果继续进行慢性透析则存活2.9年。在过去四十年中,所有亚组的标准化死亡率均下降:从2005年起,接受肾移植的患者为3.9年,移植物s失败的患者为11.5年,透析患者为32.5年。所有患者中最常见的死亡原因是缺血性心脏病(45%),其次是感染(18%),这在透析患者中更常见。由此可见,肾移植是1型糖尿病和终末期肾病患者的首选治疗方法,因为与透析相比,肾移植可显著降低死亡风险。即使肾移植功能丧失,死亡风险仍然大大降低。虽然多年来整体死亡率有所下降,但缺血性心脏病导致的过早死亡仍然很高。

【5】严重低血糖血管结局和死亡的影响

DOI:10.2337/dc18-1144


近日,一项新的研究中研究人员旨在通过退伍军人事务糖尿病试验(VADT)确定严重低血糖的危险因素,以及严重低血糖与严重心血管不良事件、心血管和全因死亡率之间的关联。这项来自VADT数据的事后分析纳入了1791名退伍军人,且为血糖控制欠佳的2型糖尿病患者,随机分配至标准(HbA1c<8.5%)和强化(HbA1c<7.0%)血糖控制组。结果显示,强化治疗组严重低血糖发生率为每100患者每年10.3人,而标准治疗组为每100患者每年3.7人。在多变量分析中,基线时胰岛素使用、蛋白尿和自主神经病变是严重低血糖的独立危险因素,BMI较高是保护性因素。过去3个月内严重低血糖与严重心血管事件、心血管死亡率和总死亡率的风险增加有关。然而,与强化血糖控制比,标准血糖控制组的总死亡风险增加相对较大。随着总体心血管风险增加,严重低血糖和心血管事件之间的关联显著增加。由此可见,在过去3个月内发生的严重低血糖事件与主要心血管事件和心血管及全因死亡风险增加有关,无论血糖治疗组如何分配。标准治疗进一步增加了严重低血糖后全因死亡的风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760990, encodeId=25301e609900a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 11 13:09:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902199, encodeId=a71b1902199a6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 22 19:09:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638965, encodeId=b7be16389658a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 06 08:09:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359221, encodeId=4bf1359221dc, content=盘点糖尿病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Jan 25 19:48:16 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358695, encodeId=c5a035869589, content=1型糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 20 09:47:59 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358664, encodeId=dcd535866486, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 19 22:42:57 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760990, encodeId=25301e609900a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 11 13:09:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902199, encodeId=a71b1902199a6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 22 19:09:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638965, encodeId=b7be16389658a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 06 08:09:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359221, encodeId=4bf1359221dc, content=盘点糖尿病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Jan 25 19:48:16 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358695, encodeId=c5a035869589, content=1型糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 20 09:47:59 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358664, encodeId=dcd535866486, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 19 22:42:57 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760990, encodeId=25301e609900a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 11 13:09:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902199, encodeId=a71b1902199a6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 22 19:09:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638965, encodeId=b7be16389658a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 06 08:09:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359221, encodeId=4bf1359221dc, content=盘点糖尿病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Jan 25 19:48:16 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358695, encodeId=c5a035869589, content=1型糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 20 09:47:59 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358664, encodeId=dcd535866486, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 19 22:42:57 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760990, encodeId=25301e609900a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 11 13:09:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902199, encodeId=a71b1902199a6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 22 19:09:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638965, encodeId=b7be16389658a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 06 08:09:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359221, encodeId=4bf1359221dc, content=盘点糖尿病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Jan 25 19:48:16 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358695, encodeId=c5a035869589, content=1型糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 20 09:47:59 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358664, encodeId=dcd535866486, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 19 22:42:57 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-25 jyzxjiangqin

    盘点糖尿病的治疗。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1760990, encodeId=25301e609900a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 11 13:09:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902199, encodeId=a71b1902199a6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 22 19:09:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638965, encodeId=b7be16389658a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 06 08:09:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359221, encodeId=4bf1359221dc, content=盘点糖尿病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Jan 25 19:48:16 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358695, encodeId=c5a035869589, content=1型糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 20 09:47:59 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358664, encodeId=dcd535866486, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 19 22:42:57 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-20 jyzxjiangqin

    1型糖尿病患者的治疗。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1760990, encodeId=25301e609900a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jun 11 13:09:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902199, encodeId=a71b1902199a6, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Jun 22 19:09:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638965, encodeId=b7be16389658a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 06 08:09:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359221, encodeId=4bf1359221dc, content=盘点糖尿病的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Fri Jan 25 19:48:16 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358695, encodeId=c5a035869589, content=1型糖尿病患者的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Jan 20 09:47:59 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358664, encodeId=dcd535866486, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Jan 19 22:42:57 CST 2019, time=2019-01-19, status=1, ipAttribution=)]
    2019-01-19 天地飞扬

    了解一下,谢谢分享!

    0